Note 15 - Segment Information - Schedule of Segment Reporting Information (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2025	Dec. 31, 2024
Licensing revenue	$ 0	$ 850
Research and development expense	55,969	42,342
General and administrative expense	16,870	15,133
Other income	6,350	7,250
Net loss	(66,489)	(49,375)
Personnel [Member]
Research and development expense	11,935	9,918
General and administrative expense	10,236	10,472
General [Member]
Research and development expense	4,616	3,965
General and administrative expense	6,634	4,661
Tovecimig [Member]
Research and development expense	23,680	23,177
CTX-471 [Member]
Research and development expense	4,183	2,879
CTX-8371 [Member]
Research and development expense	3,355	2,403
CTX-10726 [Member]
Research and development expense	$ 8,200	$ 0